DMP diabetes mellitus type 1: IQWiG identifies need for updating
15.08.2023 16:14
Preliminary results of the guideline research show: Numerous aspects of the DMP diabetes mellitus type 1 should or could be revised. Please comment on the preliminary report by September 12, 2023.
On behalf of the Federal Joint Committee (G-BA) has the Institute for Quality and Efficiency in Health Care (IQWiG) identified current evidence-based guidelines for the treatment of type 1 diabetes mellitus to compare their recommendations with the Disease Management Program Requirements Guideline (DMP-A-RL) and identify any discrepancies. For the present one Preliminary report evaluated the team of scientists IQWiG more than 1,070 recommendations from 23 evidence-based guidelines.
Preliminary conclusion: Numerous aspects of the DMP Diabetes mellitus type 1 differ from the current guideline recommendations or could be supplemented. These include, for example, differentiated therapy planning, insulin substitution and metabolic self-control, the management of concomitant and secondary illnesses, the treatment of children and adolescents and training for insured persons. In addition, the scientists identified additional aspects of care that had not yet been included DMP be addressed.
Comments on the preliminary report are possible until September 12, 2023.
Type 1 diabetes mellitus and disease management programs
Disease management programs (DMPs) are structured treatment programs for chronically ill people that are based on evidence-based medicine. They are intended to ensure that those affected receive care that prevents consequential damage and worsening of the disease as much as possible and improves their quality of life. The content requirements for a DMP are regularly checked to ensure they are up to date. In December 2022, there were around 260,000 people with statutory health insurance in Germany DMP Diabetes mellitus type 1 enrolled.
Type 1 diabetes mellitus is a chronic disease in which the insulin-producing cells in the pancreas are irretrievably destroyed by immune cells. Typical symptoms of type 1 diabetes mellitus are frequent urination, weight loss, a strong feeling of thirst as well as tiredness and exhaustion. If blood sugar concentrations are very high, impaired consciousness or loss of consciousness can also occur.
If the disease is not treated, it can lead to serious and irreversible damage to small and large blood vessels and nerve tracts. Typical accompanying and secondary diseases that can occur in the advanced stages of type 1 diabetes mellitus primarily affect the eyes, kidneys and nervous system. In addition, those affected have an increased risk for the occurrence of cardiovascular diseases.
About the reporting process
The G-BA has the IQWiG on November 17, 2022 with a guideline synopsis to update the DMP Diabetes mellitus type 1 commissioned. An external expert was involved in the processing of the project. This preliminary report is a preliminary assessment. Comments on the preliminary report that has now been published are possible until September 12, 2023 and will be reviewed after the deadline. If the statements leave any questions unanswered, those commenting will be invited to an oral discussion. This is then created IQWiG the Final report.